Butein Induces White Adipocyte Differentiation to Beige

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for inducing brown adipocytes and beige adipocytes are inadequate in effectively addressing obesity and metabolic diseases, as they do not sufficiently regulate the activity of uncoupling protein-1 (UCP-1) and promote the genesis of these beneficial adipocytes.

Innovation Solution

A composition comprising butein or a butein derivative is used to induce differentiation of white adipocytes into beige adipocytes, increasing the expression of UCP-1 and PRDM4, thereby enhancing the activity of brown adipocytes and improving metabolic health.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current methods for inducing brown adipocytes and beige adipocytes are used, then some adipocyte differentiation occurs, but the activity of uncoupling protein-1 (UCP-1) is not sufficiently regulated and the genesis of beneficial adipocytes is inadequate

Engineering Contradiction:
Improveeffectiveness of obesity treatmentVSAvoidinduction efficiency of beige adipocytes
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by optimizing the concentration and treatment duration of butein to maximize UCP-1 expression and beige adipocyte differentiation. By systematically varying these parameters, the invention achieves superior induction efficiency compared to conventional methods, directly addressing the inadequacy of current approaches in promoting beneficial adipocyte genesis

Inventive Principle:
Principle #35Parameter changes

2Use of energy by moving object

If white adipocytes are converted to beige adipocytes through existing methods, then some metabolic improvement occurs, but UCP-1 expression and calorie burning are not sufficiently enhanced

Engineering Contradiction:
Improvecalorie burningVSAvoidmetabolic disease treatment efficacy
Core Design Contradiction:
Use of energy by moving objectVSReliability

Solution Approach 1:

The patent uses butein as an intermediary substance that mediates the conversion of white adipocytes to beige adipocytes and activates UCP-1 expression. This natural compound acts as a bridge between the existing adipocyte population and the desired metabolic state, enhancing calorie burning and improving metabolic disease treatment efficacy through its specific biochemical interactions

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of butein or its derivatives effectively increases the expression of UCP-1 and PRDM4, leading to a decrease in body weight, improved glucose-insulin metabolism, and enhanced calorie burning, making it a promising approach for treating obesity and metabolic diseases.

Implementation Method 1

inducing differentiation into beige adipocytes from white adipocytes

Methodology Applied
Scientific EffectCell differentiation:

Implementation Method 2

increasing the expression of UCP-1 and PRDM4

Methodology Applied
Scientific EffectGene expression regulation:

Implementation Method 3

uncoupling protein-1 (UCP-1) is expressed on a high level from the brown adipocytes, and plays a critical role in generating heat in the form of calorie burning

Methodology Applied
Scientific EffectThermogenesis:

Implementation Method 4

may be induced by maintenance of a body temperature through heat generation

Methodology Applied
Scientific EffectHeat generation:

Data Source

PatentUS9877946B2Method for treating, managing, inhibiting, or preventing obesity
Publication Date: 2018.01.30 RAPPELER CO LTD
  • US9877946B2 patent drawing
  • US9877946B2 patent drawing
  • US9877946B2 patent drawing

AI summary

A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.